BioLamina

Mike Rohan

🇹🇷 Turkey

9.4

Reviewed: November 8, 2023

• - Health Technology Assessment
• - 10 weeks September - November 2023
• - Pharmaceutical Company

The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.

Lee Braun

🇮🇳 India

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Danielle Zulauf

🇧🇷 Brazil

8.8

Reviewed: May 15, 2024

• - Companion Diagnostics Development
• - 16 weeks January - May 2024
• - Pharmaceutical Company

The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.

Yolanda Hermann IV

🇪🇸 Spain

9.2

Reviewed: August 20, 2024

• - Regulatory Strategy Consulting
• - 4 weeks July - August 2024
• - Biotech Startup

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Edgar Altenwerth

🇳🇱 Netherlands

9.1

Reviewed: April 6, 2024

• - HTA Submission
• - 8 weeks February - March 2024
• - Biotech Company

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.